Justmet V 50 Tablet contains Vildagliptin 50 mg, an oral antihyperglycemic agent used in the management of type 2 diabetes mellitus. Vildagliptin belongs to the class of dipeptidyl peptidase-4 (DPP-4) inhibitors, which enhance the body's incretin system by preventing the degradation of incretin hormones such as GLP-1 and GIP. These hormones increase insulin secretion from pancreatic beta cells and decrease glucagon release from alpha cells in a glucose-dependent manner, thereby improving glycemic control without causing significant hypoglycemia. Justmet V 50 is indicated as monotherapy in patients inadequately controlled by diet and exercise alone, or as combination therapy with other antidiabetic agents including metformin, sulfonylureas, or insulin when monotherapy is insufficient. It is generally well tolerated, with a low risk of weight gain and hypoglycemia compared to other antidiabetic drugs. Common adverse effects may include headache, nasopharyngitis, and gastrointestinal disturbances. Caution is advised in patients with renal impairment, and dose adjustment may be necessary. Regular monitoring of blood glucose levels and renal function is recommended during therapy. Justmet V 50 Tablet should be used as part of a comprehensive diabetes management plan including diet, exercise, and lifestyle modification.